
Presentation for CDC advisers appears to cite nonexistent study to support claims about risk of vaccine preservative
But the study doesn't appear to exist.
Lyn Redwood, a former leader of Children's Health Defense, an anti-vaccine group that lists US Health and Human Services Secretary Robert F. Kennedy Jr. as a founder, is scheduled to give the presentation Thursday at a meeting of the CDC's Advisory Committee on Immunization Practices.
The slides, posted online Tuesday, cite a 2008 study in the journal Neurotoxicology by 'Berman RF, et al,' called 'Low-level neonatal thimerosal exposure: Long-term consequences in the brain.' The presentation claimed that results from a study in newborn rats suggest long-term 'neuroimmune effects' from the vaccine preservative.
The citation appears to refer to Dr. Robert F. Berman, a professor emeritus at the University of California Davis, whose research has focused on brain injury and neurodevelopmental disorders.
However, 'I don't have a publication in Neurotoxicology by that title,' Berman told CNN. 'The reference in the slide set, as far as I know – at least with me as a coauthor – does not exist.'
Berman did publish a paper with a similar title in 2008, but it was in a different journal and involved different animals. It also came to dramatically different conclusions.
'My study was published in Toxicological Sciences and did not find evidence of thimerosal exposure at vaccine levels in mouse behaviors that we thought were relevant to autism,' Berman said. He was 'concerned and displeased' that his research appeared to have been cited in this way in Redwood's slides.
Redwood's presentation was taken off the CDC website later Tuesday and replaced with a version that does not include Berman's citation.
The citation was first flagged by Dr. David Boulware, an infectious diseases professor at the University of Minnesota, who told CNN, 'The conclusion on that slide seemed really strong and definitive, and thus I wanted to look up the paper to see if the results matched their interpretation of it. … And I couldn't find the citation.'
Neither Redwood nor HHS immediately responded to CNN's request for comment on the presentation.
The presentation already was controversial because thimerosal has been a focus of advocates who claim, against evidence, that it may cause autism because it contains a form of mercury. The preservative was taken out of most vaccines about 25 years ago as a precaution, and no evidence of neurodevelopmental effects has been found in multiple studies.
Redwood, though, said in a video posted last month on Children's Health Defense's website that she believes thimerosal in pediatric vaccines led to her son's autism.
The topic was a last-minute addition to the vaccine advisers' agenda this week, sparking concerns among public health experts that it would raise debunked claims about vaccine safety. It was added after Kennedy dismissed all 17 previous experts on the influential vaccine panel, claiming they had conflicts of interest, and replaced them days later with eight new members.
Those members have raised concerns from the public health world and across the political spectrum, with Sen. Bill Cassidy, the Louisiana doctor who chairs the Senate Health, Education, Labor, and Pensions Committee, calling this week for the meeting to be postponed 'until the panel is fully staffed with more robust and balanced representation – as required by law – including those with more direct relevant expertise.'
It's also not the first time a report in Kennedy's realm has been found to have faulty citations. The initial version of the Trump administration's Make America Healthy Again report, released last month and focused on children's health, also cited some studies that don't exist. An HHS spokesperson called them 'minor citation and formatting errors.'
In a hearing before the House Energy and Commerce Health Subcommittee on Tuesday, Kennedy was questioned by Rep. Raul Ruiz, a Democrat and doctor from California, about the MAHA report errors.
'Why did the report include a citation to sources that don't even exist?' Ruiz asked. 'How does that happen under your leadership?'
Kennedy insisted that 'all of the foundational assertions in that report are accurate' and said the mistaken citations 'were corrected within 24 hours.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Autism diagnoses occurring earlier for boys, girls often wait years, analysis finds
Autism is being diagnosed earlier in young children, especially in boys, according to a major new analysis of medical records published on Tuesday. Conducted by Epic Research -- the data and analytics arm of the electronic health record software company, Epic Systems -- the analysis also found that many girls still face years-long delays in receiving a diagnosis and an increasing share of women are not diagnosed until adulthood. This raises concerns about missed opportunities for early support, Dr. Catherine Lord, the George Tarjan Distinguished Professor of Psychiatry and Education in the David Geffen School of Medicine at UCLA, told ABC News. MORE: RFK Jr. lays out new studies on autism, shuts down 'better diagnoses' as a cause "There is evidence that girls are often diagnosed later than boys, and particularly girls with milder symptoms are missed entirely," Lord, who was not involved in the analysis, said. "When you add in adults seeking a diagnosis later in life -- often more women than men -- it pushes the average age of diagnosis for females even higher." The study reviewed records from more than 338,000 patients who received their first autism spectrum disorder diagnosis between 2015 and 2024, using aggregated electronic health record data from hospitals and clinics nationwide to study health care trends. While not peer-reviewed, Epic Research's work is vetted internally by the company's clinical and research experts. The median age at diagnosis for all children fell from age 7 in 2015 to age 6 in 2024, the analysis suggested. For boys, the median age dropped from age 7 to age 5, with nearly half diagnosed before age 5 in 2024. Girls showed no similar shift, the analysis found. Their median age of diagnosis remained at about age 8, and only about one-third were diagnosed before age 5. The disparity persisted into adulthood, with one in four women first diagnosed at age 19 or older, compared with about one in eight men, the analysis found. Although the median age for diagnosis dropped, the average age remained at about 10.5 years old, likely implying that some people were being diagnosed much later, potentially into adulthood. Early detection matters because therapies, school accommodations, and interventions -- often involving speech-language pathologists, occupational therapists and developmental pediatricians -- are most effective when started early in life, Lord explained. "The biggest time of change particularly in developing language, is in the early years," Lord said. "Interventions can speed up learning and help prevent later anxiety and depression by making life easier for autistic kids and their families." MORE: RFK Jr.'s comments on autism draw reactions from parents and experts Early signs of autism can include limited eye contact, not responding to their name, delayed speech, repetitive behaviors such as hand-flapping or lining up objects, intense or unusual interests, and distress over changes in routine, according to the Centers for Disease Control and Prevention (CDC) , In girls, these signs may be harder to notice or focused on socially typical topics, which can delay recognition. For families facing barriers to diagnosis, Lord recommended seeking evaluations through schools, contacting state-run early intervention programs for children under age three. She also recommended relying on credible sources such as the CDC, Autism Speaks and the Autism Science Foundation for more information. "There's much more hope now for autism," she said. "Not to 'cure' it, but to support people, figure out their strengths, and help them find their place in the world." Christian S. Monsalve, MD is a functional psychiatry fellow and a member of the ABC News Medical Unit. Solve the daily Crossword
Yahoo
36 minutes ago
- Yahoo
Brandon Blackstock's death at 48 puts spotlight on melanoma
The death of talent manager and producer Brandon Blackstock, Kelly Clarkson's ex-husband, at the age of 48, is shining a spotlight on melanoma. Dan Hollis, the Butte-Silver Bow County coroner in Montana, confirmed to ABC News that Blackstock's cause of death was natural and due to melanoma. Hollis also said Blackstock died at his home in Butte, Montana, on Aug. 7. The Blackstock family announced last Thursday that Brandon Blackstock had "bravely battled cancer for more than three years" and that he died "peacefully" and "was surrounded by family." Read on for more information about melanoma. Brandon Blackstock, ex-husband of Kelly Clarkson, has died, family confirms What is melanoma? Melanoma is a type of skin cancer that begins in the melanocytes, or the cells that produce melanin in the body, according to the Centers for Disease Control and Prevention. It is often caused by overexposure to ultraviolet or UV rays from the sun, sun lamps or tanning beds. Melanoma is considered to be one of the deadliest forms of skin cancer, according to a 2024 study published in the journal BMC Cancer, because it tends to spread to other parts of the body. The CDC estimates about 8,000 people in the U.S. die from melanoma annually. Skin cancer overall is the most common type of cancer in the U.S., according to the CDC. Woman shares warning after tiny mark on cheek turns out to be cancer Who is at risk for melanoma? The CDC notes that anyone can get skin cancers like melanoma. Certain people may be more at risk for melanoma, including older adults; people with a family history or personal history with skin cancer; people with lighter skin or skin that easily reddens, burns or freckles; people with blue or green eyes or blond or red hair; and anyone who has a history of sunburns or tanning. The importance of sunscreen Because melanoma is often caused by UV rays, the American Academy of Dermatology stresses the use of sunscreen as one way to prevent skin cancers like melanoma. The AAD recommends using broad-spectrum and water-resistant sunscreen with an SPF of 30 or higher, applying at least a shot-glass amount of sunscreen, and re-applying every two hours when outdoors, swimming or sweating. Additional ways to prevent skin cancer, according to the AAD, include wearing other forms of sun protection such as long-sleeved clothing, a wide-brimmed hat, and sunglasses; seeking shade, avoiding the sun midday when UV rays are the strongest; and avoiding tanning beds. How to screen for melanoma Some dermatologists recommend regular skin self-checks, especially for people who have a history or skin cancer. There is currently no standard guidance for skin checks, according to the CDC. The AAD recommends self-screening for melanoma by following the "ABCDE" method: Asymmetry: Look for any moles that are not symmetrical, or where half of the mole doesn't look like the other half. Border: Look for any moles with irregular, ragged or scalloped borders. Color: Look for any moles that vary in color, such as any with a red, white or blue color. Diameter: Look for any moles that are more than 6 millimeters in diameter, about greater than the size of a pencil eraser. Evolving: Look for any moles that have changed in any form or have started to itch or bleed. How is melanoma diagnosed? Doctors may examine any moles and look for potential signs of melanoma by using a magnifying dermatoscope or a visual aid device. Doctors will also likely take photos of any concerning moles and shave any concerning moles for a biopsy or tissue exam. How is melanoma treated? There are various treatment options for melanoma. According to the National Cancer Institute, doctors may treat melanoma with chemotherapy, immunotherapy, radiation, surgery or targeted therapy.
Yahoo
36 minutes ago
- Yahoo
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing. There are approximately 500,000 people in the U.S. diagnosed with NCFB. The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW ASPEN, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients who received Brinsupri 25 mg experienced a statistically significantly less decline in lung function, as measured by forced expiratory volume in one second (FEV₁) after using a bronchodilator, at week 52. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions in WILLOW. In parallel, applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory. Price Action: INSM stock is up 6.20% at $119.89 at the last check on Tuesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INSMED (INSM): Free Stock Analysis Report This article FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data